Nuwellis Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nuwellis Inc 's ROA in the second quarter of 2026?
Nuwellis Inc recorded a cumulative net loss of $-11 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -150.12%.

However, within the Healthcare sector 810 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4536, from total ROA ranking in the first quarter of 2026 at 5233.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-0.8 %	-0.64 %	-37.98 %	18.67 %	48.65 %
Y / Y Net Income Change	-	-	-	-80.07 %	-
Net Income (TTM) in million	-11	-19	-18	-17	-15
Return On Assets (TTM)	-150.12 %	-251.86 %	-231.36 %	-194.53 %	-178.95 %
NUWE's Total Ranking	# 4536	# 5233	# 4592	# 4654	# 4637
Total Assets (TTM) in million	9	7	6	8	9
Seq. Total Assets Change	31.1 %	13.78 %	-23.37 %	-13.22 %	31.32 %
Seq. Net Income Change	-	-	-	-	-

NUWE's 5 Years Annual ROA >> Back to NUWE Management Effectiveness >> Compare NUWE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 187
Sector	# 811
Overall	# 4360

Return On Assets Statistics
High	Average	Low
-49.65 %	-119.11 %	-251.86 %
(Jun 30 2014)		(Mar 31 2026)

News about Nuwellis Inc Return on Assets ROA

Nuwellis Secures $2.0 Million Funding to Transform Fluid Overload Treatment

Nuwellis Announces Pricing of $2.0 Million Offering to Fuel Growth in Fluid Overload Treatment Sector
MINNEAPOLIS, July 24, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, has recently closed a successful public offering to raise $2.0 million. The offering, priced at-the-market under Nasdaq rules, involved the purchase and sale of 469,340 shares of the Company s common stock to certain institutional investors.
This recent development represents a significant step forward for Nuwellis, as it seeks to address the growing needs of individuals suffering from fluid overload. The company has been dedicated to finding innovative solutions to improve the quality of life for these patients, and this funding will enable it to further advance its research and development efforts.

Nuwellis Inc's New Real-World Data Show Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

Nuwellis, Inc., a company dedicated to improving the lives of individuals suffering from fluid overload, recently released new real-world data highlighting the clinical benefits of using ultrafiltration therapy with hematocrit monitoring for pediatric patients. The data demonstrates that the hematocrit sensor within the Nuwellis Aquadex system offers unique advantages for fluid overloaded small patients.
This significant development comes at a crucial time for Nuwellis Inc, as the company s year-to-date performance has been challenging. In the 12 months ending in the third quarter of 2023, Nuwellis Inc recorded a cumulative net loss of $17 million, resulting in a negative return on assets of -94.65%. However, with the release of these promising real-world data, there is renewed hope for the company s future.

Financial Statements
Nuwellis Inc 's Assets	$ 9 million	NUWE's Balance sheet
Nuwellis Inc 's Income	$ -5 million	Quarterly NUWE's Income Statement
NUWE's Income by Division		See NUWE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	526.08 %	0.96 %	-60.4 %	-18.88 %	51.99 %
Total Assets in million	62	10	10	25	30
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-18	-10	-20	-15	-20
Annual Return On Assets	-28.37 %	-102.22 %	-208.09 %	-58.87 %	-64.37 %

NUWE's 5 Years Annual ROA >> Back to NUWE Management Effectiveness >> Compare NUWE ROA to its Competitors

More Return On Assets Ratios
NUWE's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NUWE's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NUWE's Competitors
Subscribers only: Roa for Nuwellis Inc 's Suppliers
Subscribers only: Return On Assets for NUWE's Customers

You may also want to know
NUWE's Roi	NUWE's Inventory Turnover Ratio	NUWE's Growth Rates	NUWE's Dividend Comparisons
	NUWE's Profitability Ratios	NUWE's Asset Turnover Ratio	NUWE's Dividend Growth
NUWE's Roe	NUWE's Valuation Ratios	NUWE's Financial Strength Ratios	NUWE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T12:04:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.